2020
The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis
Martinez L, Cords O, Horsburgh C, Andrews J, Consortium P, Acuna-Villaorduna C, Ahuja S, Altet N, Augusto O, Baliashvili D, Basu S, Becerra M, Bonnet M, Boom W, Borgdorff M, Boulahbal F, Carvalho A, Cayla J, Chakhaia T, Chan P, Cohen T, Croda J, Datta S, del Corral H, Denholm J, Dietze R, Dobler C, Donkor S, Egere U, Ellner J, Espinal M, Evans C, Fang C, Fielding K, Fox G, García L, García-Basteiro A, Geis S, Graham S, Grandjean L, Hannoun D, Hatherill M, Hauri A, Hesseling A, Hill P, Huang L, Huerga H, Hussain R, Jarlsberg L, Jones-López E, Kato S, Kato-Maeda M, Kampmann B, Kirchner H, Kritski A, Lange C, Lee C, Lee L, Lee M, Lemos A, Lienhardt C, Ling D, Liu Q, Lo N, Long R, Lopez-Varela E, Lu P, Magee M, Malone L, Mandalakas A, Martinson N, Mazahir R, Murray M, Netto E, Otero L, Parsonnet J, Reingold A, Schaaf H, Seddon J, Sharma S, Singh J, Singh S, Sloot R, Sotgiu G, Stein C, Iqbal N, Triasih R, Trieu L, van der Loeff M, Van der Stuyft P, van Schalkwyk C, Vashishtha R, Verhagen L, Villalba J, Wang J, Whalen C, Yoshiyama T, Zar H, Zellweger J, Zhu L. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. The Lancet 2020, 395: 973-984. PMID: 32199484, PMCID: PMC7289654, DOI: 10.1016/s0140-6736(20)30166-5.Peer-Reviewed Original ResearchConceptsYears of agePreventive therapyIncident tuberculosisTuberculosis infectionHazard ratioTuberculosis casesMixed-effects Poisson regression modelsSystematic reviewFinal analysisClose exposureIncident tuberculosis casesRisk of tuberculosisDevelopment of tuberculosisEMBASE electronic databasesIndividual participant dataPositive resultsPoisson regression modelsWeb of ScienceMixed-effects logistic modelBCG vaccinationCohort studyBaseline visitPrevalent tuberculosisContact investigationProspective study
2018
Risk ratios for contagious outcomes
Morozova O, Cohen T, Crawford FW. Risk ratios for contagious outcomes. Journal Of The Royal Society Interface 2018, 15: 20170696. PMID: 29343627, PMCID: PMC5805970, DOI: 10.1098/rsif.2017.0696.Peer-Reviewed Original Research
2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016, 30: 2715-2723. PMID: 27782966, PMCID: PMC5089846, DOI: 10.1097/qad.0000000000001235.Peer-Reviewed Original ResearchConceptsContinuous isoniazid preventive therapyIsoniazid preventive therapyIsoniazid-resistant tuberculosisTB epidemicPreventive therapyEffective TB treatmentLatent TB infectionTB drug resistanceTransmission dynamic modelTB infectionMortality benefitTB treatmentHIV controlHIV incidenceTB incidenceTB transmissionCase findingDrug resistanceIncidenceTuberculosisInitial benefitPLHIVHIVTherapyEpidemicTradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis
Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLOS Medicine 2016, 13: e1002142. PMID: 27727274, PMCID: PMC5058480, DOI: 10.1371/journal.pmed.1002142.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisMDR-TB treatmentTB treatmentSecondary casesDrug-resistant (XDR) TBResistance patternsLife expectancyMultidrug-resistant TB patientsDrug bedaquilineMDR-TB drugsAnti-tuberculosis drug bedaquilineCulture conversionMDR patientsTB patientsMortality benefitBedaquiline resistanceMedian timeRisk of resistanceTB drugsDecrease transmissionHypothetical cohortSources of heterogeneityDrug interactionsInitial cohortTime of initiation
2015
Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis
Chindelevitch L, Menzies NA, Pretorius C, Stover J, Salomon JA, Cohen T. Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis. Journal Of The Royal Society Interface 2015, 12: 20150146. PMID: 25878131, PMCID: PMC4424692, DOI: 10.1098/rsif.2015.0146.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyTB incidenceTB burdenBurden of tuberculosisTuberculosis Control ProgrammePotential epidemiological impactART eligibilityMortality benefitTB programsHIV treatmentTB prevalenceTuberculosis incidenceEpidemiological impactART useProgram improvementHIVTreatment effectivenessIncidenceMortalityGreater reductionBurdenTBSaharan AfricaControl programsEligibility
2014
Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates
Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Pérez-Vélez CM, Pagano M, Becerra MC, Cohen T. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. The Lancet 2014, 383: 1572-1579. PMID: 24671080, PMCID: PMC4094366, DOI: 10.1016/s0140-6736(14)60195-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolGlobal HealthHumansIncidenceInfantRisk AssessmentTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisMultidrug-resistant tuberculosis diseaseTreatment-naive adultsMultidrug-resistant diseaseTuberculosis diseaseTuberculosis incidenceGlobal incidenceSystematic reviewCases of tuberculosisHarvard Medical SchoolGlobal tuberculosis incidenceGlobal annual incidenceTuberculosis riskAnnual incidencePatient groupUS National InstitutesWomen's HospitalInclusion criteriaInternal medicineNew diagnostic instrumentDisease riskTuberculosisIncidenceDiseaseHealth equity
2012
Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 812-6. PMID: 22507372, PMCID: PMC3786434, DOI: 10.5588/ijtld.11.0637.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsChi-Square DistributionDrug Resistance, BacterialDrug Therapy, CombinationEthambutolFemaleGeorgia (Republic)HumansIsoniazidLogistic ModelsMaleMicrobial Sensitivity TestsMiddle AgedMultivariate AnalysisMycobacterium tuberculosisPredictive Value of TestsPyrazinamideRetrospective StudiesRifampinRisk AssessmentRisk FactorsSputumTime FactorsTreatment OutcomeTuberculosisConceptsPulmonary tuberculosisPrevious treatmentOutcomes of patientsPulmonary TB patientsSubset of patientsRetrospective record reviewForms of tuberculosisFirst-line drugsHigh TB ratesDrug-resistant formsLower ratesLow tuberculosisTB patientsTuberculosis patientsOptimal management strategyTreatment regimenRecord reviewTB ratesTreatment successTreatment outcomesCountry of GeorgiaPatientsIsoniazid resistanceTuberculosisDrug resistance